^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MRC1 expression

    i
    Other names: MRC1, Mannose Receptor C-Type 1, CLEC13DL, BA541I19.1, Human Mannose Receptor, Macrophage Mannose Receptor 1, CLEC13D, Macrophage Mannose Receptor 1-Like Protein 1, C-Type Lectin Domain Family 13 Member D, Mannose Receptor, C Type 1-Like 1, MMR, CD206, MRC1L1, HMR, C-Type Lectin Domain Family 13 Member D-Like, Macrophage Mannose Receptor, Mannose Receptor, C Type 1, CD206 Antigen
    Entrez ID:
    4360
    1year
    IGF2BP3/CTCF Axis-Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas. (PubMed, Clin Respir J)
    The IGF2BP3/CTCF axis-dependent NT5DC2 promotes M2 macrophage polarization, thereby enhancing the malignant progression of LUSC. This study was the first to reveal the role of NT5DC2 in LUSC and the underlying mechanism. The result suggests that targeting the IGF2BP3/CTCF/NT5DC2 axis may have clinical significance in the treatment of LUSC.
    Journal
    |
    IL10 (Interleukin 10) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    |
    CD20 expression • ITGAM expression • MRC1 expression
    1year
    Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma. (PubMed, Cancer Immunol Immunother)
    Furthermore, α5-nAChR expression was strongly linked to pSTAT3, SOX2 and M2 macrophage marker CD206 expression and negatively correlated with M1 macrophage marker CD86 expression in vivo. It is indicated that M2 macrophages are mediated by the new α5-nAChR /SOX2/CSF-1 axis in nicotine-related LUAD, which is a potential therapeutic strategy for cancer.
    Journal
    |
    CSF1 (Colony stimulating factor 1) • SOX2 • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
    |
    CSF1 expression • MRC1 expression • SOX2 expression
    1year
    Oral squamous cell carcinomas drive monocytes into immunosuppressive CD25+CD163+CD206+ macrophages. (PubMed, Oral Oncol)
    CD25 enhanced expression was confirmed on H143-CM moMΦ. Collectively, these data indicate that the CM from OSCC cell lines promotes the differentiation of functionally immunosuppressive macrophages resembling TAMs, and contributes to the understanding of how OSCCs create an immunosuppressive cellular environment that favors tumor growth.
    Journal
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • ITGAX (Integrin Subunit Alpha X) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CD163 expression • MRC1 expression
    1year
    Qingrexiaoji Recipe Regulates the Differentiation of M2 TAM via miR-29 in GC. (PubMed, Comb Chem High Throughput Screen)
    In summary, these results suggested that the Qingrexiaoji recipe regulated M2 macrophage polarization by regulating miR-29a-3p/HDAC4, providing a different and innovative treatment for gastric cancer.
    Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule) • HDAC4 (Histone Deacetylase 4) • MIR29A (MicroRNA 29a)
    |
    CD20 expression • IFNG expression • MRC1 expression
    1year
    CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment. (PubMed, J Microbiol Biotechnol)
    In vivo silencing of CKAP2 repressed tumor growth and metastasis. Overall, CKAP2 was positively regulated by TFDP1, which promoted tumorigenesis and metastasis in CRC.
    Journal
    |
    IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
    |
    MRC1 expression
    1year
    Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment. (PubMed, J Exp Clin Cancer Res)
    CRC-derived exosomal miR-106a-5p plays a critical role in promoting liver metastasis and is a potential biomarker for the prevention and treatment of CRC liver metastasis.
    Journal • Metastases
    |
    MIR106A (MicroRNA 106a) • MRC1 (Mannose Receptor C-Type 1)
    |
    MRC1 expression
    1year
    NEIL3 upregulated by TFAP2A promotes M2 polarization of macrophages in liver cancer via the mediation of glutamine metabolism. (PubMed, Digestion)
    This study suggested that the TFAP2A/NEIL3 axis promoted Mø M2 polarization through Gln metabolism, providing a theoretical basis for immune therapy targeting the liver cancer TME.
    Journal
    |
    IL10 (Interleukin 10) • CCR2 (C-C Motif Chemokine Receptor 2) • MRC1 (Mannose Receptor C-Type 1) • NEIL3 (Nei Like DNA Glycosylase 3) • CD86 (CD86 Molecule) • TFAP2A (Transcription Factor AP-2 Alpha)
    |
    MRC1 expression
    1year
    Integrins α5β1 and αvβ3 Differentially Participate in the Recruitment and Reprogramming of Tumor-associated Macrophages in the In Vitro and In Vivo Models of Breast Tumor. (PubMed, J Immunol)
    In line with this, FAK inhibition during TAM polarization reduced SRC, STAT1, and STAT6 phosphorylation. In conclusion, these findings underscore the crucial role of integrins in TAM recruitment, polarization, and reprogramming in tumors.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • IL10 (Interleukin 10) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • MRC1 (Mannose Receptor C-Type 1)
    |
    MERTK expression • CD20 expression • MRC1 expression
    1year
    CD206 accelerates hepatocellular carcinoma progression by regulating the tumour immune microenvironment and increasing M2-type polarisation of tumour-associated macrophages and inflammation factor expression. (PubMed, Discov Oncol)
    The overexpression of CD206 accelerates the progression of HCC and changes the tumour immune microenvironment. The high expression of CD206 in HCC increases the M2-type polarisation of TAMs and induces the expression of both TGF-β and IL-6 in tumour tissues and serum, thereby promoting HCC progression.
    Journal
    |
    IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1)
    |
    CD20 expression • CD20 overexpression • CD2 overexpression • IL6 expression • MRC1 expression
    1year
    Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer. (PubMed, BMC Cancer)
    Our study presents novel findings on mechanism of 2ME2 from the perspective of its effects on the polarization of the TAMs via the STAT3 signaling in breast cancer. Altogether, the data supports further clinical investigation of 2ME2 and its derivatives as therapeutic agents to modulate the tumor microenvironment and immune response in breast carcinoma.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • MRC1 (Mannose Receptor C-Type 1) • CCL18 (C-C Motif Chemokine Ligand 18)
    |
    CD20 expression • CD163 expression • MRC1 expression
    |
    Panzem (2-methoxyestradiol)
    over1year
    Microglia-targeted inhibition of miR-17 via mannose-coated lipid nanoparticles improves pathology and behavior in a mouse model of Alzheimer's disease. (PubMed, Brain Behav Immun)
    This selective targeting strategy delivers specific agents to microglia without the adverse off-target effects on other cell types. Additionally, this approach can be used to deliver other molecules to microglia and other immune cells in other organs.
    Preclinical • Journal
    |
    MIR17 (MicroRNA 17) • MRC1 (Mannose Receptor C-Type 1)
    |
    MRC1 expression
    over1year
    TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway. (PubMed, Biochem Biophys Res Commun)
    TM6SF1-caused inhibition of proliferation, migration, invasion and EMT, as M2 macrophage polarization was reversed by the PI3K activator in LUAD cells. TM6SF1 inactivated the PI3K/AKT/mTOR pathway to suppress LUAD malignancy and polarization of M2 macrophages, providing insight for developing new LUAD treatments.
    Journal
    |
    CDH1 (Cadherin 1) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • MRC1 (Mannose Receptor C-Type 1) • TM6SF1 (Transmembrane 6 Superfamily Member 1)
    |
    CDH1 expression • MRC1 expression